K Maijer1, M J H Begemann1, S J M C Palmen1, S Leucht2, I E C Sommer1. 1. Department of Psychiatry,University Medical Center Utrecht and Brain Center Rudolf Magnus,Heidelberglaan 100, 3485CX Utrecht,The Netherlands. 2. Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar,Ismaningerstr. 22, 81675 München,Germany.
Abstract
BACKGROUND: Auditory Hallucinations (AH) are nowadays regarded as symptoms following a continuum; from a (transient) phenomenon in healthy individuals on one end to a symptom of (psychiatric) illnesses at the other. An accumulating number of epidemiological studies focused on the prevalence of AH in the general population, but results vary widely. The current meta-analysis aims to synthesize existing evidence on lifetime prevalence of AH across the lifespan. METHODS: We conducted a quantitative review and meta-analysis according to PRISMA guidelines. Studies were combined to calculate a mean lifetime general population AH prevalence rate. Moreover, prevalences were calculated for four age groups: children (5-12 years), adolescents (13-17 years), adults (18-60 years) and elderly (⩾60 years). RESULTS: We retrieved 25 study samples including 84 711 participants. Mean lifetime prevalence rate of AH was 9.6% (95% CI 6.7-13.6%). The mean lifetime prevalence was similar in children (12.7%) and adolescents (12.4%), but these two groups differed significantly from the adults (5.8%) and the elderly (4.5%). Significant heterogeneity indicated that there is still dispersion in true prevalence rates between studies, even within the different age categories. CONCLUSIONS: Current meta-analysis shows that AH are quite common (up to one in ten individuals) in the general population during lifetime, with children and adolescents reporting these experiences significantly more often compared with adults and elderly. Large follow-up studies on the longitudinal course of AH are needed to reveal associated risk and resilience factors.
BACKGROUND: Auditory Hallucinations (AH) are nowadays regarded as symptoms following a continuum; from a (transient) phenomenon in healthy individuals on one end to a symptom of (psychiatric) illnesses at the other. An accumulating number of epidemiological studies focused on the prevalence of AH in the general population, but results vary widely. The current meta-analysis aims to synthesize existing evidence on lifetime prevalence of AH across the lifespan. METHODS: We conducted a quantitative review and meta-analysis according to PRISMA guidelines. Studies were combined to calculate a mean lifetime general population AH prevalence rate. Moreover, prevalences were calculated for four age groups: children (5-12 years), adolescents (13-17 years), adults (18-60 years) and elderly (⩾60 years). RESULTS: We retrieved 25 study samples including 84 711 participants. Mean lifetime prevalence rate of AH was 9.6% (95% CI 6.7-13.6%). The mean lifetime prevalence was similar in children (12.7%) and adolescents (12.4%), but these two groups differed significantly from the adults (5.8%) and the elderly (4.5%). Significant heterogeneity indicated that there is still dispersion in true prevalence rates between studies, even within the different age categories. CONCLUSIONS: Current meta-analysis shows that AH are quite common (up to one in ten individuals) in the general population during lifetime, with children and adolescents reporting these experiences significantly more often compared with adults and elderly. Large follow-up studies on the longitudinal course of AH are needed to reveal associated risk and resilience factors.
Entities:
Keywords:
Adolescents; adults; auditory hallucinations; children; epidemiology; general population; prevalence
Authors: Y van der Steen; I Myin-Germeys; M van Nierop; M Ten Have; R de Graaf; S van Dorsselaer; J van Os; R van Winkel Journal: Epidemiol Psychiatr Sci Date: 2018-04-16 Impact factor: 6.892
Authors: Sara Siddi; Susana Ochoa; Aida Farreny; Gildas Brébion; Frank Larøi; Jorge Cuevas-Esteban; Josep Maria Haro; Christian Stephan-Otto; Antonio Preti Journal: Int J Methods Psychiatr Res Date: 2018-09-20 Impact factor: 4.035
Authors: Mascha M J Linszen; Janna N de Boer; Maya J L Schutte; Marieke J H Begemann; Jacqueline de Vries; Sanne Koops; Renske E Blom; Marc M Bohlken; Sophie M Heringa; Jan Dirk Blom; Iris E C Sommer Journal: Schizophrenia (Heidelb) Date: 2022-04-23
Authors: Lindsay A Bornheimer; Meghan E Martz; Takakuni Suzuki; Ivy F Tso; Cynthia Z Burton; Juliann Li Verdugo; Tyler Grove; Mary M Heitzeg; Stephan F Taylor Journal: Schizophr Bull Date: 2022-05-07 Impact factor: 7.348
Authors: Marialuisa Cavelti; Janko M Kaeser; Stefan Lerch; Stephanie Bauer; Markus Moessner; Thomas Berger; Mark Hayward; Michael Kaess Journal: Trials Date: 2022-10-23 Impact factor: 2.728
Authors: Robert C Wolf; Mahmoud Rashidi; Mike M Schmitgen; Stefan Fritze; Fabio Sambataro; Katharina M Kubera; Dusan Hirjak Journal: Schizophr Bull Date: 2021-03-16 Impact factor: 9.306
Authors: Alyssa Jongeneel; Dorien Scheffers; Nynke Tromp; Chani Nuij; Philippe Delespaul; Heleen Riper; Mark van der Gaag; David van den Berg Journal: BMJ Open Date: 2018-03-06 Impact factor: 2.692